

Technical Bulletin

Monoclonal ANTI-FLAG® M2-FITC antibody produced in mouse

Clone M2, purified immunoglobulin, buffered aqueous glycerol solution

F4049

Product Description

Monoclonal ANTI-FLAG® M2-FITC is a purified IgG₁ monoclonal antibody isolated from a mouse cell culture,¹ covalently conjugated to fluorescein isothiocyanate (FITC). The antibody conjugate binds to FLAG® fusion proteins. It will recognize the FLAG® sequence at the N-terminus, Met-N-terminus or C-terminus of FLAG® fusion proteins. This conjugate is useful for identification of FLAG® fusion proteins by common immunological procedures.

Monoclonal ANTI-FLAG® M2-FITC may be used for the detection of FLAG® fusion proteins. It can be used in fluorescent immunocytochemistry and immunohistochemistry. The conjugate can also be used in Western blot and flow cytometry applications. Several theses⁵ and dissertations⁶⁻²¹ cite use of this product in their research.

Reagent

This product is supplied as a solution in 10 mM sodium phosphate (pH 7.4), 150 mM NaCl, 1% bovine serum albumin, and 0.1% sodium azide.

F/P molar ratio: 3.0-6.0

Specificity: The antibody has been found to detect FLAG-BAP™ fusion protein in transfected COS cells.

Precautions and Disclaimer

For R&D use only. Not for drug, household, or other uses. Please consult the Safety Data Sheet for information regarding hazards and safe handling practices.

Preparation Instructions

Dilute the antibody to the recommended working dilution in Tris-Buffered Saline (TBS): 0.05 M Tris, 0.15 M NaCl, pH 7.4.

Storage/Stability

Store undiluted antibody at -20 °C in working aliquots. Repeated freezing and thawing is **not** recommended.

Product Profile

Suggested working dilutions

Immunocytochemistry, Immunohistochemistry and Western blotting: an antibody concentration of 1-10 µg/mL may be used.

Flow cytometry: an antibody concentration of ≤ 5 µg/mL may be used.

To obtain optimal results, it is recommended that each individual user determine the working dilution by titration assay.

Procedure

Procedure for Direct Immunofluorescent Staining of Mammalian Cells

1. Wash cells grown in a culture dish or on a slide with TBS twice.
2. Fix cells with a freshly prepared mixture of methanol:acetone (1:1) for 1 minute at room temperature.
3. Wash cells with TBS four times.
4. Incubate cells with Monoclonal ANTI-FLAG® M2-FITC at 10 µg/mL in TBS at room temperature for 1 hour.
5. Wash cells with TBS twice.
6. Examine using a fluorescence microscope with appropriate configuration for fluorescein. FITC has an absorption maximum at approximately 492 nm with an emission maximum at 520 nm.

Note: The fluorescence properties of FITC and FITC conjugates are pH-dependent.²⁻⁴

References

1. Brizzard, B.L. *et al.*, *BioTechniques*, **16(4)**, 730-735 (1994).
2. Chen, R.F., *Arch. Biochem. Biophys.*, **133(2)**, 263-276 (1969).
3. Klugerman, M.R., *J. Immunol.*, **95(6)**, 1165-1173 (1965).
4. Emmart, E.W., *Arch. Biochem. Biophys.*, **73(1)**, 1-8 (1958).
5. Laraki, Ghislaine, "TRBP-P ACT interaction in the regulation of HIV expression and PKR activation". McGill University, M.Sc. thesis, p. 48 (2004).
6. Reimer, Tatiana, "Cellular localization and function of peptidyl-prolyl *cis-trans* isomerase *hPar14*". Martin-Luther-Universität Halle-Wittenberg, Dr. rer. nat. dissertation, p. 25 (2003).
7. Jäckh, Christine, "Transcription factor networks directing pancreas development in *Xenopus laevis*". Georg-August Universität zu Göttingen, Ph.D. dissertation, p. 20 (2008).
8. Maussang-Detaille, David André Baptiste, "Herpesvirus-Encoded G Protein-Coupled Receptors as Modulators of Cellular Signaling Pathways". Vrije Universiteit Amsterdam, Ph.D. dissertation, p. 122 (2009).
9. Porpiglia, Ermelinda, "Digital and Analog STAT5 Signaling in Erythropoiesis". University of Massachusetts Worcester, Ph.D. dissertation, p. 135 (2011).
10. Banaszek, Agnes, "Dual Antigen-Restricted Complementation of a Two-Part Trispecific Antibody for Targeted Immunotherapy of Blood Cancer". Julius-Maximilians-Universität Würzburg, Ph.D. dissertation, p. 30 (2013).
11. Nayak, Tanmoyita, "Characterization of the functional and signaling properties of the Intracellular domain of the NG2 proteoglycan". Johannes Gutenberg-Universität Mainz, Ph.D. dissertation, p. 37 (2013).
12. Antequera, Georgina Garrido, "Involvement of the Microtubule-Regulated RhoGEF GEF-H1 in the G12 family signaling pathways". Universitat de Barcelona, Ph.D. dissertation, p. 80 (2014).
13. Blumenkrantz, Deena, "The cellular and molecular basis of transmission of influenza viruses". Imperial College London, Ph.D. dissertation, p. 283 (2014).
14. Bassi, Christian, "Nuclear PTEN controls DNA repair and sensitivity to genotoxic stress". University of Toronto, Ph.D. dissertation, p. 89 (2015).
15. Holstein, Carly Ann, "Development of a Novel Paper-Based Flu Test for Improved Diagnosis at the Point of Care". University of Washington, Ph.D. dissertation, p. 97 (2015).
16. Kim, Won Kyu, "Selective translational regulation of premature termination codon containing mutant mRNAs". Yonsei University, Ph.D. dissertation, p. 13 (June 2015).
17. Mattheis, Corinna, "Characterisation of the *L. pneumophila* effectors LtpK and LtpM". Imperial College London, Ph.D. dissertation, p. 162 (2016).
18. Wang, Bo, "High-throughput analysis of native antibody repertoires for therapeutics discovery". University of Texas at Austin, Ph.D. dissertation, p. 96 (December 2016).
19. Young, Christina A., "A Possible Role for AP-1 Transcription Factors in Development of Epidermal Ichthyoses". University of Maryland, Baltimore, Ph.D. dissertation, p. 57 (2017).
20. Cartwright, Tyrell Neko, "The Structural Basis of the p50:p50:HDAC1 Anti-inflammatory Corepressor Complex". Newcastle University, Ph.D. dissertation, p. 36 (September 2018).
21. Ehteramyan, Mazdak, "Characterisation of a novel nested encoding Laf4ir gene in the cardiovascular system". King's College London, Ph.D. dissertation, p. 89 (May 2019).

General Immunofluorescence References

22. Beesley, J.E. (ed.), *Immunocytochemistry: A Practical Approach*. IRL Press, pp. 215-216 (1993).
23. Bullock, G.R., and Petrusz, P. (eds.) *Techniques in Immunocytochemistry*, Volumes 1, 2, 3 and 4. Academic Press (1982, 1983, 1985, 1989). For example, see Vol. 1, p. 186.
24. Giloh, H., and Sedat, J.W. 'Fluorescence microscopy: Reduced photobleaching of rhodamine and fluorescein protein conjugates by n-propyl gallate'. *Science*, **217(4566)**, 1252-1255 (1982).
25. Storz, H. and Jelke, E., 'Photomicrography of weakly fluorescent objects-employment of *p*-phenylenediamine as a blocker of fading'. *Acta Histochem.*, **75(2)**, 133-139 (1984).
26. Harlow, E. and Lane, D. *Antibodies: A Laboratory Manual*, Cold Spring Harbor Press (Cold Spring Harbor, NY; 1988).
27. Johnson, G.D. *et al.*, 'Fading of immunofluorescence during microscopy: A study of the phenomenon and its remedy'. *J. Immunol. Methods*. **55(2)**, 231-242 (1982).
28. Longin, A. *et al.*, 'Comparison of anti-fading agents used in fluorescence microscopy: image analysis and laser confocal microscopy study'. *J. Histochem. Cytochem.* **41(12)**, 1833-1840 (1993).

Immunofluorescence Troubleshooting Guide²²⁻²⁸

Problem	Possible Cause	Solution
High Background	Aggregates	Centrifuge antibody conjugate briefly in microcentrifuge at highest speed to remove antibody aggregates.
	Antibody binding to Fc receptors on cell surface	Incubate sample with 10% irrelevant serum (such as goat serum, Cat. No. G9023) to occupy Fc receptors prior to applying antibody conjugate
	Wash steps not adequate	Increase the number, or the length, of washes.
	Antibody concentration not optimal	Determine optimal working dilution for the FITC conjugate by titration. Consider using less antibody if background is too high.
	Aldehydes left in the tissue by fixatives (formaldehyde and particularly glutaraldehyde) provide covalent binding sites for applied immunoreagents via their amino groups. ²²	If not sufficiently blocked by serum alone, one or more of the following can be tried: ²² (a) 0.02-1% sodium or potassium borohydride in 0.1 M phosphate buffer, pH 7.4 for 30 minutes at room temperature. (b) 50-100 mM ammonium chloride added to the blocking serum. (c) 100 mM ethanolamine added to the blocking serum. (d) 0.2 M glycine in PBS for 5 minutes.
Tissue Autofluorescence	Glutaraldehyde may induce autofluorescence in tissue and decrease antibody penetration into tissues. ²³	<ul style="list-style-type: none"> • Avoid aldehyde fixatives. • Consider preparing acetone-fixed frozen sections.
	Usually tissue autofluorescence is greenish-yellow when viewed using a fluorescein filter set-up. It may even show through using a rhodamine filter set-up.	Consider masking the autofluorescence with a fluorescent background dye. Chicago Sky Blue 6B (Pontamine Sky Blue), Cat. No. C8679, 0.05% (w/v) in PBS with 1% (v/v) dimethyl sulfoxide, fluoresces red using a fluorescein filter set-up. Tissue sections should be stained with the masking reagent 30 minutes prior to applying the primary antibody. ²²

Immunofluorescence Troubleshooting Guide (continued)²²⁻²⁸

Problem	Possible Cause	Solution
No staining	FLAG [®] not expressed on fusion protein	Verify expression of FLAG [®] tag on fusion protein by immunoblotting or other method.
	Antibody concentration not optimal	Determine optimal working dilution for FITC conjugate by titration. Consider using more antibody if no signal or weak signal is detected.
	Inappropriate filter for fluorescent microscopy	Use filter recommended for visualizing FITC: <ul style="list-style-type: none"> • Excitation maximum for FITC: 492 nm • Emission maximum for FITC: 520 nm
	Incubation time with antibody not adequate	Increase incubation time.
	FITC label quenched or faded	Avoid exposure to light. Consider using anti-fade reagent in mounting medium such as: <ul style="list-style-type: none"> • Propyl gallate²⁴ (Cat. No. P3130) • <i>p</i>-phenylenediamine dihydrochloride²⁵ (Cat. No. 78460) • 1,4-Diazabicyclo[2.2.2]octane (DABCO[®])²⁶⁻²⁸ (Cat. No. D27802)
	Cultured cells: Intracellular expression of FLAG [®] fusion protein in cultured cells not accessible by antibody	Cells need to be permeabilized: <ul style="list-style-type: none"> • Consider fixing cells in methanol at -20 °C for 10 minutes, followed by 1 minute in acetone at -20 °C. • Alternatively, try fixing cells in 3% paraformaldehyde containing 0.5% Triton[®] X-100 for 10 minutes at room temperature.
Formalin-fixed paraffin sections: Antibody does not have access to FLAG [®] tag due to cross-linking caused by aldehyde fixation.	Consider unmasking with proteases or stain frozen sections. Commonly used proteases are: <ul style="list-style-type: none"> • 0.4% pepsin (Cat. No. P7012) in 0.01 N HCl • 0.1% protease (Cat. No. P5380) in PBS • 0.1% trypsin (Cat. No. T8003) in water containing 10 mM CaCl₂ at 37 °C for 2-30 minutes. Optimal conditions must be determined empirically.	

Notice

We provide information and advice to our customers on application technologies and regulatory matters to the best of our knowledge and ability, but without obligation or liability. Existing laws and regulations are to be observed in all cases by our customers. This also applies in respect to any rights of third parties. Our information and advice do not relieve our customers of their own responsibility for checking the suitability of our products for the envisaged purpose.

The information in this document is subject to change without notice and should not be construed as a commitment by the manufacturing or selling entity, or an affiliate. We assume no responsibility for any errors that may appear in this document.

Technical Assistance

Visit the tech service page at SigmaAldrich.com/techservice.

Standard Warranty

The applicable warranty for the products listed in this publication may be found at SigmaAldrich.com/terms.

Contact Information

For the location of the office nearest you, go to SigmaAldrich.com/offices.

The life science business of Merck KGaA, Darmstadt, Germany operates as MilliporeSigma in the U.S. and Canada.

MilliporeSigma, and Sigma-Aldrich are trademarks of Merck KGaA, Darmstadt, Germany or its affiliates. All other trademarks are the property of their respective owners. Detailed information on trademarks is available via publicly accessible resources.
© 2021 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.

F4049dat Rev 11/21 AH,RS,PHC,GCY